Key considerations and common adverse events for HIV-positive patients with cancer treated with immune checkpoint inhibitors
FUTURE ONCOLOGY, cilt.18, ss.413-416, 2022 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Editöre Mektup
- Cilt numarası: 18
- Basım Tarihi: 2022
- Doi Numarası: 10.2217/fon-2021-1513
- Dergi Adı: FUTURE ONCOLOGY
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
- Sayfa Sayıları: ss.413-416
- Anahtar Kelimeler: cancer, HIV, immunotherapy, HEPATITIS, RESERVOIR, LYMPHOMA
- Ankara Üniversitesi Adresli: Evet
Özet
HIV-infected patients are more susceptible to cancer due to their immune-compromised condition and HIV infection. Chronic inflammation and immune dysregulation are the main causes of cancer development in these patients. Because of lymphopenia and an immune-compromised condition, most HIV-infected patients with cancer were not considered for cytotoxic therapies, such as chemotherapy and radiotherapy. Immune checkpoint inhibitors (ICIs) have become a game-changer in many cancer types. However, not enough prospective data is available regarding the use of ICIs in HIV-infected patients with cancer. Retrospective data from case reports/series showed that ICIs are safe in HIV-infected patients with cancer.